Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by kuatoliveson Aug 18, 2016 9:37am
113 Views
Post# 25153534

RE:Very informative article from director of Tribute

RE:Very informative article from director of TributeWhat a bozo. Why did he even bother writing such a vapid, recycled article. You'd think a director would have at least been able to contribute something beyond recycled info already out there. I responded to his article with:

As a (significant) former shareholder of Tribute, I'm am still disgusted at how Mr. Harris @ Co traded a steadily growing company providing increasing shareholder value for a MASSIVE amount of risk in a single drug (Yosprala) that still has not been approved.  Before the merger, Tribute shares were trading around $1.35 and now their equivalent value is trading somewhere around 72 cents.  How do you feel that Mr. Harris and his directors performed this merger in the best interest of investors again? Investors, at the end of the day, are interested in making money, and whether that money is made by having a large slice of a small pie or a small piece of a big pie, is irrelevant.  Tribute revenues were steadily climbing, and continue climbing to this day, with costs under control. There is no doubt in my mind, despite the sector turmoil, that Tribute would be north of $1.50 today were it left to its own devices. Again, if if ARLZ doubles up from these values (a big IF), we'd only then return to where TRX would have been sitting for the last year. 
 
 If you think this deal was so wonderful, point to me one TRX shareholder on the planet - that wasn't awarded shares for nothing - that is in the black, and hasn't been in the red for the last year biting his/her nails *hoping* yosprala gets approved and if it does, the management team who took over tribute can also execute on growing its sales. 
 
Again, all of that shareholder value was traded for a massive amount of risk that is one letter from the FDA away from being, at best, returned after maybe ANOTHER year of waiting, or at worst, completely annihilated in the event of another delay. And you're going to sit there with a straight face and tell me this deal was in the best interest of shareholders? 
<< Previous
Bullboard Posts
Next >>